Medmain

From Wikipedia, the free encyclopedia

Other names2-Methyl-3-ethyl-5-dimethylaminoindole
Drug classSerotonin receptor modulator; Serotonin antagonist or partial agonist; Convulsant
ATC code
  • None
CAS Number
Medmain
Clinical data
Other names2-Methyl-3-ethyl-5-dimethylaminoindole
Drug classSerotonin receptor modulator; Serotonin antagonist or partial agonist; Convulsant
ATC code
  • None
Identifiers
  • 3-ethyl-N,N,2-trimethyl-1H-indol-5-amine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC13H18N2
Molar mass202.301 g·mol−1
3D model (JSmol)
  • CCC1=C(NC2=C1C=C(C=C2)N(C)C)C
  • InChI=1S/C13H18N2/c1-5-11-9(2)14-13-7-6-10(15(3)4)8-12(11)13/h6-8,14H,5H2,1-4H3
  • Key:IOYNGCZNYGEZRO-UHFFFAOYSA-N

Medmain, also known as 2-methyl-3-ethyl-5-dimethylaminoindole, is a serotonin receptor modulator, convulsant, and indole derivative related to the neurotransmitter serotonin.[1][2][3][4] It has low-potency serotonin antagonist or partial agonist activity, with low affinity for serotonin 5-HT1 and 5-HT2 receptors (IC50Tooltip half-maximal inhibitory concentration = >1,000 nM) but greater activity against the serotonin receptors in the rat stomach fundus strip (KB = 50 nM) (thought to represent the serotonin 5-HT2B receptor).[4][5][2] Owing to its convulsant activity, medmain was tested in animals but not in humans.[3] The drug was described and studied by E. Shaw and Dilworth Woolley in the 1950s.[4][2][3] A derivative, 1-methylmedmain, is also known, and has similar potency as a serotonin antagonist but lacks the convulsant activity of medmain.[3][4][6] Other analogues of medmain have been explored as well, but none had improved activity at the rat fundus strip serotonin 5-HT2B receptor compared to medmain and 1-methylmedmain.[4][5]

Related Articles

Wikiwand AI